• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

  • Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • Countering AMR
  • COVID-19 Research
  • Digital Therapies
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

OHE Welcomes Patrick Holmes to the Board of Trustees

In December, OHE announced that Professor Mike Drummond , Professor Bengt Jonnson, and Louise Timlin were stepping down from the OHE Board of Trustees. OHE is pleased to welcome Patrick Holmes to the Board of Trustees effective 31 January 2022.…

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for PolicymakersRead more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes
  • PhRMA

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
When Generic Measures Fail to Reflect What Matters to Patients: Three Case StudiesRead more
© NCI/Unsplash
  • Health Technology Assessment…
  • Measuring and Valuing Outcomes
  • Canada

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Cancer_WellcomeCollection_landscape
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic TherapiesRead more
© WellcomeCollection
Close
OHE
  • All Publications

    Filter by:
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • Countering AMR
    • COVID-19 Research
    • Digital Therapies
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 28th March 2022

OHE Welcomes Patrick Holmes to the Board of Trustees

In December, OHE announced that Professor Mike Drummond , Professor Bengt Jonnson, and Louise Timlin were stepping down from the OHE Board of Trustees. OHE is pleased to welcome Patrick Holmes to the Board of Trustees effective 31 January 2022.…

Tim 3
Tim Watson
Share:

In December, OHE announced that Professor Mike Drummond , Professor Bengt Jonnson, and Louise Timlin were stepping down from the OHE Board of Trustees.

OHE is pleased to welcome Patrick Holmes to the Board of Trustees effective 31 January 2022. OHE’s Chief Executive, Professor Graham Cookson says, “We’re delighted to welcome Patrick Holmes to the Board. He is a well-renowned expert on developing global policy initiatives to drive affordable patient access to innovative medicines which is core to OHE’s mission.”

Patrick Holmes is an industry veteran with over 30 years of experience in the pharmaceutical industry in a broad range of roles, most notably in the global policy arena.  Patrick is the Science and Innovation Policy Lead at Pfizer based in New York and heads a team responsible for developing global health policy initiatives and evidence across a series of policy issues supporting Pfizer’s R&D-driven organization, including driving affordable patient access to medicines, while allowing the company to continue to develop and deliver innovative treatments. Issue areas include market-based R&D incentives, value and innovation frameworks and sustainable patient-centric health systems. All areas of significant interest to OHE’s researchers.

As more than 80% of OHE’s consultancy work is international, Patrick will bring invaluable oversight and counsel to OHE’s executive team. He has significant experience of working on topics such as AMR that OHE is well-known for, and with international and multilateral organisations such as Business @ OECD Health Committee, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Value and Access and Pandemic Preparedness Working Groups, Innovation and Value Initiative (IVI) Scientific Advisory Panel and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Healthcare Systems Working Group. Further, as OHE continues to develop a portfolio of research and consulting in the US policy arena Patrick’s experience with the US health system will be invaluable.

Patrick brings a range of experiences to his current role having worked across multiple areas of the biopharmaceutical business during his 30-year career at Pfizer. Patrick joined Pfizer as a marketing associate in 1990 and held multiple positions of increasing responsibility in both US and global marketing spanning a range of therapeutic areas including hypertension, lipid lowering, arrhythmia, diabetes, erectile dysfunction, and allergies. Patrick then switched to a strategic planning role where he was responsible for evaluating new product opportunities and providing strategic input on behalf of the US commercial organization. He then led the Portfolio and Decision Analysis group, supporting strategic decisions and investment tradeoffs across Pfizer’s development portfolio. His last assignment prior to joining the policy team was Vice President, Strategy and Portfolio Support, providing comprehensive insights and identifying key emerging trends for Pfizer leaders.

Patrick has a BA in biology from Middlebury College and an MS in management from the Massachusetts Institute of Technology Sloan School of Management. He joins the Board in a personal capacity.

 

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
patientcare_shutterstock_1190997985_landscape
  • News
  • May 2022

Patient Participation Awareness Week 2022

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 OHE

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!